Egyptian drugmaker Minapharm Pharmaceuticals plans to start production at its new genetic engineering factory in Berlin at the end of this year, its deputy chairperson said on Sunday.
Based on German experience, the new factory will manufacture genetic engineering drugs.
“The new plant has begun test production,” Dina Soliman said, adding that her company seeks to expand in pharmaceutical manufacturing through the genetic engineering and the new generation medicines by setting up two factories, one in Germany and the other in Egypt.
“The total investment costs of the two factories are expected to reach 3 billion Egyptian pounds ($168 million), Soliman said.
“As for our anticipated factory in Egypt, we may begin the actual production by 2020,” Soliman said in previous statement to reporters.
